IL160142A0 - Methods and compounds for the targeting of protein to exosomes - Google Patents
Methods and compounds for the targeting of protein to exosomesInfo
- Publication number
- IL160142A0 IL160142A0 IL16014202A IL16014202A IL160142A0 IL 160142 A0 IL160142 A0 IL 160142A0 IL 16014202 A IL16014202 A IL 16014202A IL 16014202 A IL16014202 A IL 16014202A IL 160142 A0 IL160142 A0 IL 160142A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- relates
- membrane vesicles
- well
- exosomes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31315901P | 2001-08-17 | 2001-08-17 | |
US34399101P | 2001-12-26 | 2001-12-26 | |
PCT/EP2002/009108 WO2003016522A2 (fr) | 2001-08-17 | 2002-08-14 | Procedes et composes pour le ciblage de proteines vers des exosomes |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160142A0 true IL160142A0 (en) | 2004-06-20 |
Family
ID=26978714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16014202A IL160142A0 (en) | 2001-08-17 | 2002-08-14 | Methods and compounds for the targeting of protein to exosomes |
Country Status (10)
Country | Link |
---|---|
US (1) | US7704964B2 (fr) |
EP (1) | EP1417229B1 (fr) |
JP (1) | JP4662708B2 (fr) |
CN (1) | CN100590131C (fr) |
AT (1) | ATE512982T1 (fr) |
AU (1) | AU2002331244B2 (fr) |
CA (1) | CA2454756C (fr) |
HK (1) | HK1062444A1 (fr) |
IL (1) | IL160142A0 (fr) |
WO (1) | WO2003016522A2 (fr) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704964B2 (en) | 2001-08-17 | 2010-04-27 | Exothera L.L.C. | Methods and compounds for the targeting of protein to exosomes |
US7354897B2 (en) * | 2002-06-07 | 2008-04-08 | Brigham & Women's Hospital, Inc. | Method and composition for inhibiting or slowing blood coagulation |
US7914792B2 (en) * | 2003-02-14 | 2011-03-29 | Exothera L.L.C. | Methods and compounds for raising antibodies and for screening antibody repertoires |
US7771956B2 (en) * | 2003-06-30 | 2010-08-10 | Brigham & Women's Hospital, Inc. | Method for detecting the presence of a phospholipid |
WO2005037229A2 (fr) * | 2003-10-17 | 2005-04-28 | Emory University | Procedes et compositions conçus pour moduler l'adherence des gametes |
US9321822B2 (en) * | 2005-05-13 | 2016-04-26 | The Feinstein Institute For Medical Research | Milk fat globule epidermal growth factor—factor VIII and sepsis |
CN1322115C (zh) * | 2005-07-06 | 2007-06-20 | 清华大学 | 载有外源配体分子的胞外体及其制备方法与应用 |
US8288172B2 (en) * | 2006-03-09 | 2012-10-16 | Aethlon Medical, Inc. | Extracorporeal removal of microvesicular particles |
US9085778B2 (en) * | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
EP2117305A4 (fr) * | 2007-01-26 | 2011-03-30 | Univ Louisville Res Found | Modification de composants à base d' exosome utilisés comme vaccin |
BRPI0817261A2 (pt) | 2007-09-24 | 2015-06-30 | Univ Queensland | Vesícula de entrega molecular |
FR2928926B1 (fr) * | 2008-03-18 | 2015-08-21 | Centre Nat Rech Scient | Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes |
EP2358912B1 (fr) * | 2008-10-30 | 2016-10-12 | Caris Life Sciences Switzerland Holdings GmbH | Procédés d'évaluation de motifs arn |
GB2463401B (en) | 2008-11-12 | 2014-01-29 | Caris Life Sciences Luxembourg Holdings S A R L | Characterizing prostate disorders by analysis of microvesicles |
JP5713325B2 (ja) | 2009-04-17 | 2015-05-07 | アイシス イノヴェイション リミテッド | 遺伝物質の送達用の組成物 |
FR2950350B1 (fr) * | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
WO2011097480A1 (fr) * | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Compositions exosomales et procédés pour le traitement de maladies |
KR20130056855A (ko) | 2010-03-01 | 2013-05-30 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 치료진단용 생물학적 지표들 |
AU2011237669B2 (en) | 2010-04-06 | 2016-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
CA2807942C (fr) | 2010-08-10 | 2021-07-27 | Ecole Polytechnique Federale De Lausanne | Agents therapeutiques se liant aux erythrocytes |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9816998B2 (en) | 2011-04-01 | 2017-11-14 | Cornell University | Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers |
ITRM20110403A1 (it) | 2011-07-28 | 2013-01-29 | Ospedale Pediatrico Bambino Gesu | Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori. |
KR20130032646A (ko) * | 2011-09-23 | 2013-04-02 | 삼성전자주식회사 | 막단백질 및 광발생 단백질이 결합된 융합단백질을 포함하는 재조합 엑소좀을 이용한 엑소좀 수득율을 측정하는 방법 |
GB201121070D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
US10233219B2 (en) | 2013-04-12 | 2019-03-19 | Tufts Medical Center | Methods and systems for designing and/or characterizing soluble lipidated ligand agents |
JP6542197B2 (ja) | 2013-04-12 | 2019-07-10 | エヴォックス・セラピューティクス・リミテッド | 治療的送達小胞 |
US10877033B2 (en) | 2013-06-18 | 2020-12-29 | Oxford University Innovation Limited | Method of detecting the presence or absence of autoantibodies |
GB201313249D0 (en) * | 2013-07-25 | 2013-09-11 | Isis Innovation | Method |
EP2862874B1 (fr) | 2013-10-15 | 2018-12-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Procédé de production d'anticorps polyclonaux à l'aide d'une composition antigénique comprenant des vésicules de membrane contenant des protéines |
US20160243192A1 (en) * | 2013-10-17 | 2016-08-25 | Children's Hospital Los Angeles | Antibody dependent exosome therapy |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
MX2016010835A (es) | 2014-02-21 | 2017-07-11 | Anokion Sa | Terapeuticos dirigidos a la glucosa. |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
CN105859837B (zh) * | 2014-10-22 | 2020-11-20 | 台北医学大学 | 胆固醇酯转运蛋白抗原肽和融合蛋白以及其组合物和应用 |
KR20160130937A (ko) * | 2015-05-04 | 2016-11-15 | 한국과학기술원 | 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법 |
US10702581B2 (en) * | 2015-05-04 | 2020-07-07 | Ilias Biologics Inc. | Compositions containing protein loaded exosome and methods for preparing and delivering the same |
EP3307890A1 (fr) | 2015-06-10 | 2018-04-18 | Board of Regents, The University of Texas System | Utilisation d'exosomes pour le traitement de maladies |
US9840542B2 (en) | 2015-09-11 | 2017-12-12 | Nomadogen Biotechnologies Inc. | Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells |
WO2017118764A1 (fr) * | 2016-01-07 | 2017-07-13 | Thomas Brocker | Nouvelles approches pour la visualisation in vivo et in vitro de cellules mourantes |
EP3405208B1 (fr) | 2016-01-22 | 2020-04-29 | Tufts Medical Center, Inc. | Composés et procédés pour le traitement de l'inflammation |
IL260988B2 (en) | 2016-03-03 | 2023-03-01 | Roussy Inst Gustave | ptps-based vaccines against cancer |
WO2017173367A2 (fr) | 2016-03-31 | 2017-10-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vésicules extracellulaires, leurs procédés de préparation, et méthodes de réduction de l'absorption hépatique des vésicules extracellulaires |
WO2017175253A1 (fr) * | 2016-04-04 | 2017-10-12 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Vaccin à adn ciblant l'exosome |
EP3356522A4 (fr) * | 2016-09-30 | 2019-03-27 | Cellex Life Sciences, Incorporated | Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants |
US10487143B2 (en) * | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
CN108324735B (zh) * | 2017-01-20 | 2024-02-09 | 李莉 | 用于疾病治疗的胞外体制剂及其应用 |
CN107185612B (zh) * | 2017-03-17 | 2020-12-01 | 庶安永龄(厦门)健康产业有限公司 | 一种应用于外泌体捕获的微流体芯片及其制备方法 |
WO2018208971A1 (fr) * | 2017-05-10 | 2018-11-15 | University Of Louisville Research Foundation, Inc. | Compositions comprenant des exosomes dérivés de cellules souches embryonnaires génétiquement modifiées et leur procédé d'utilisation |
EP3638296A1 (fr) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions et procédés d'induction d'une tolérance immunitaire |
US11938219B2 (en) | 2017-07-29 | 2024-03-26 | University Of Southern California | Synthetic extracellular vesicles for novel therapies |
WO2019067464A1 (fr) * | 2017-09-27 | 2019-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | Agents thérapeutiques spécifiquement administrés par des exosomes pour le traitement du cancer |
BR112020013131A2 (pt) * | 2017-12-28 | 2020-12-08 | Codiak Biosciences, Inc. | Exossomos para imuno-oncologia e terapia anti-inflamatória |
US20210030850A1 (en) * | 2018-04-10 | 2021-02-04 | Northwestern University | Extracellular vesicles comprising targeting affinity domain-based membrane proteins |
US20220409741A1 (en) * | 2019-09-02 | 2022-12-29 | Kyungpook National University Industry-Academic Cooperation Foundation | Composition for preventing or treating cancer, containing il-2 surface expression-extracellular vesicles as active ingredient |
CN112824530A (zh) * | 2019-11-20 | 2021-05-21 | 中国科学院深圳先进技术研究院 | 一种hek293f悬浮细胞高效电转染方法 |
EP4093408A4 (fr) * | 2020-01-22 | 2024-04-24 | AgeX Therapeutics, Inc. | Exosomes thérapeutiques et leur procédé de production |
JP2023512562A (ja) | 2020-02-05 | 2023-03-27 | ダイアデム バイオセラピューティクス インコーポレイテッド | 人工シナプス |
MX2024006801A (es) | 2021-12-06 | 2024-08-09 | Ciloa | Polipeptidos quimericos de adiponectina, vesicula extracelular que los comprende y usos de los mismos. |
CN116676265B (zh) * | 2023-04-18 | 2024-05-24 | 河南中医药大学第一附属医院 | 一种酸敏融合肽靶向外泌体及其制备方法和应用 |
CN116769717B (zh) * | 2023-04-18 | 2024-06-11 | 河南中医药大学第一附属医院 | 一种靶向外泌体及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972337A (en) * | 1990-11-01 | 1999-10-26 | Cancer Research Fund Of Contra Costa | 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein |
US5455031A (en) | 1990-11-01 | 1995-10-03 | Cancer Research Fund Of Contra Costa | Polypeptide with 46 Kdalton HMFG differentiation antigen binding specificity, composition, kit and diagnostic method |
IT1264516B1 (it) | 1993-05-31 | 1996-09-24 | Biotop Sas Di Rita Cassarin | Cellule dendritiche immortalizzate |
AU6632496A (en) | 1995-08-03 | 1997-03-05 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
US5834015A (en) | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
FR2785543B1 (fr) | 1998-11-05 | 2003-02-28 | Inst Nat Sante Rech Med | Exosomes modifies et utilisations |
EP1004664A1 (fr) * | 1998-11-24 | 2000-05-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions et procédés utilisant la lactadhérine ou des dérivés de celle-ci |
FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
US20040241176A1 (en) | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
US6410271B1 (en) | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Generation of highly diverse library of expression vectors via homologous recombination in yeast |
CA2431212A1 (fr) | 2000-12-27 | 2002-07-25 | Richard T. Wyatt | Proteoliposomes immunogenes et applications de ceux-ci |
US7704964B2 (en) | 2001-08-17 | 2010-04-27 | Exothera L.L.C. | Methods and compounds for the targeting of protein to exosomes |
EP1483372A2 (fr) | 2002-03-14 | 2004-12-08 | Anosys, Inc. | Vesicules derivees de lymphocytes t, production et utilisations |
-
2002
- 2002-08-14 US US10/485,360 patent/US7704964B2/en not_active Expired - Fee Related
- 2002-08-14 CN CN02816094A patent/CN100590131C/zh not_active Expired - Fee Related
- 2002-08-14 AU AU2002331244A patent/AU2002331244B2/en not_active Ceased
- 2002-08-14 IL IL16014202A patent/IL160142A0/xx unknown
- 2002-08-14 JP JP2003521831A patent/JP4662708B2/ja not_active Expired - Fee Related
- 2002-08-14 EP EP02767380A patent/EP1417229B1/fr not_active Expired - Lifetime
- 2002-08-14 AT AT02767380T patent/ATE512982T1/de not_active IP Right Cessation
- 2002-08-14 CA CA2454756A patent/CA2454756C/fr not_active Expired - Fee Related
- 2002-08-14 WO PCT/EP2002/009108 patent/WO2003016522A2/fr active Application Filing
-
2004
- 2004-06-03 HK HK04103989.3A patent/HK1062444A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1543476A (zh) | 2004-11-03 |
EP1417229A2 (fr) | 2004-05-12 |
WO2003016522A2 (fr) | 2003-02-27 |
JP2005503791A (ja) | 2005-02-10 |
ATE512982T1 (de) | 2011-07-15 |
CA2454756A1 (fr) | 2003-02-27 |
JP4662708B2 (ja) | 2011-03-30 |
AU2002331244B2 (en) | 2007-02-15 |
CA2454756C (fr) | 2014-02-18 |
CN100590131C (zh) | 2010-02-17 |
US20040197314A1 (en) | 2004-10-07 |
HK1062444A1 (en) | 2004-11-05 |
WO2003016522A3 (fr) | 2003-08-28 |
EP1417229B1 (fr) | 2011-06-15 |
US7704964B2 (en) | 2010-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL160142A0 (en) | Methods and compounds for the targeting of protein to exosomes | |
BG104149A (en) | Interleukin-18-binding proteins, methods for their preparation and administration | |
MXPA02012106A (es) | Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion. | |
BG100771A (en) | Hematopoeic protein and ways and methods for its preparation | |
AU6063500A (en) | Glycoprotein vi and uses thereof | |
EP1304382A3 (fr) | Production de peptides dans des végétaux par fusions de protéines d'enveloppes virales | |
MXPA02010670A (es) | Nuevas moleculas co-estimuladoras de celula dendritica. | |
WO2003083056A3 (fr) | Secretion de proteines a plusieurs liaisons disulfure chez des bacteries et leur utilisation | |
DE69013342D1 (de) | Menschliche lactoferrin-cdna-sequenz. | |
WO1995019435A3 (fr) | Proteines de la region v du recepteur d'antigene des lymphocytes t et leurs procedes de preparation | |
WO2001085782A3 (fr) | Recepteur de la famille tnf | |
AU1172202A (en) | Far red shifted fluorescent proteins | |
WO1999019470A3 (fr) | Proteines de fusion de la gfp et de l'annexine | |
WO2002068459A3 (fr) | Proteines fluorescentes anti-agregantes et leurs methodes d'utilisation | |
WO2000059942A3 (fr) | COMPOSITIONS hOB-BP2h, LEURS TECHNIQUES ET LEURS UTILISATIONS | |
ATE295890T1 (de) | Vektor zur expression von n-terminal verlängerten proteinen in hefezellen | |
WO2002081623A3 (fr) | Acides nucleiques a cycle cellulaire, polypeptides et utilisations correspondantes | |
WO2000012710A8 (fr) | Acides nucleiques codant pour des proteines de liaison a l'ataxine-2, produits y relatifs et procedes utilisant ces acides nucleiques et ces proteines | |
WO2000018909A3 (fr) | Acides nucleiques et proteines provenant de cenarchaeum symbiosum | |
WO2002094992A3 (fr) | Evolution dirigee de proteine dans des cellules de mammifere | |
GB0116460D0 (en) | Biological products | |
AU6310100A (en) | Single-chain polypeptides comprising troponin i n-terminal fragments and troponin | |
WO2002002771A3 (fr) | Nouveau gene hsparc-11 et procedes de fabrication et d'utilisation de ce dernier | |
WO1999024835A3 (fr) | Immuno-essai pour propeptide de procollagene iii a terminal c | |
EP1892251A3 (fr) | Acides nucléiques et polypeptides apparentés à B7 utiles pour effectuer une immunomodulation |